Indoco Remedies Limited (Indoco) announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga, following a successful Inspection of the said facility from 15th September, 2025 to 19th September, 2025.

Aditi Panandikar, Managing Director, Indoco said, "We are pleased to have received the EIR from the USFDA for our API manufacturing facility located at Patalganga. This further reinforces our commitment to upholding the highest standards of quality and compliance, delivering trusted healthcare solutions to patients worldwide."